MAPK inhibitors (MAPKi) show outstanding clinical response rates in melanoma patients harbouring BRAF mutations, but resistance is common. High-throughput, subcellular proteome analyses at two differe
Western blot images for manuscript entitled "Synchronization of transcription steps defines the major bottlenecks in HIV-1 latency reactivation" by Hyder, Challa et al.
